Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

NCT04016714 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1191

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

DRUG: V114
DRUG: Prevenar 13™
DRUG: Vaxelis™
DRUG: M-M-R®II
DRUG: VARIVAX™

Sponsor

Merck Sharp & Dohme LLC